Cargando…
Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke
BACKGROUND: Lipid lowering agent such as agonists of peroxisome proliferator-activated receptors (PPAR) are suggested as neuroprotective agents and may protect from the sequelae of brain ischemic stroke. Although the demonstration is not clearly established in human, the underlying molecular mechani...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061923/ https://www.ncbi.nlm.nih.gov/pubmed/24944524 http://dx.doi.org/10.1186/1477-5956-12-24 |
_version_ | 1782321572574396416 |
---|---|
author | Gelé, Patrick Vingtdeux, Valérie Potey, Camille Drobecq, Hervé Ghestem, Antoine Melnyk, Patricia Buée, Luc Sergeant, Nicolas Bordet, Régis |
author_facet | Gelé, Patrick Vingtdeux, Valérie Potey, Camille Drobecq, Hervé Ghestem, Antoine Melnyk, Patricia Buée, Luc Sergeant, Nicolas Bordet, Régis |
author_sort | Gelé, Patrick |
collection | PubMed |
description | BACKGROUND: Lipid lowering agent such as agonists of peroxisome proliferator-activated receptors (PPAR) are suggested as neuroprotective agents and may protect from the sequelae of brain ischemic stroke. Although the demonstration is not clearly established in human, the underlying molecular mechanism may be of interest for future therapeutic purposes. To this end, we have used our well established rodent model of ischemia-reperfusion pre-treated or not with fenofibrate or atorvastatin and performed a differential proteomics analyses of the brain and analysed the protein markers which levels returned to “normal” following pre-treatments with PPARα agonists. RESULTS: In order to identify potential therapeutic targets positively modulated by pre-treatment with the PPARα agonists, two-dimensional gel electrophoresis proteome profiles between control, ischemia-reperfusion and pre-treated or not, were compared. The polypeptide which expression was altered following ischemia – reperfusion but whose levels remain unchanged after pre-treatment were characterized by mass spectrometry and further investigated by Western-blotting and immunohistochemistry. A series of 28 polypeptides were characterized among which the protein disulfide isomerase reduction – a protein instrumental to the unfolded protein response system - was shown to be reduced following PPARα agonists treatment while it was strongly increased in ischemia-reperfusion. CONCLUSIONS: Pre-treatment with PPARα agonist or atorvastatin show potential neuroprotective effects by inhibiting the PDI overexpression in conjunction with the preservation of other neuronal markers, several of which are associated with the regulation of protein homeostasis, signal transduction and maintenance of synaptic plasticity. This proteomic study therefore suggests that neuroprotective effect of PPARα agonists supposes the preservation of the expression of several proteins essential for the maintenance of protein homeostasis not necessarily directly linked to PPARα known-regulated targets. |
format | Online Article Text |
id | pubmed-4061923 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40619232014-06-19 Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke Gelé, Patrick Vingtdeux, Valérie Potey, Camille Drobecq, Hervé Ghestem, Antoine Melnyk, Patricia Buée, Luc Sergeant, Nicolas Bordet, Régis Proteome Sci Research BACKGROUND: Lipid lowering agent such as agonists of peroxisome proliferator-activated receptors (PPAR) are suggested as neuroprotective agents and may protect from the sequelae of brain ischemic stroke. Although the demonstration is not clearly established in human, the underlying molecular mechanism may be of interest for future therapeutic purposes. To this end, we have used our well established rodent model of ischemia-reperfusion pre-treated or not with fenofibrate or atorvastatin and performed a differential proteomics analyses of the brain and analysed the protein markers which levels returned to “normal” following pre-treatments with PPARα agonists. RESULTS: In order to identify potential therapeutic targets positively modulated by pre-treatment with the PPARα agonists, two-dimensional gel electrophoresis proteome profiles between control, ischemia-reperfusion and pre-treated or not, were compared. The polypeptide which expression was altered following ischemia – reperfusion but whose levels remain unchanged after pre-treatment were characterized by mass spectrometry and further investigated by Western-blotting and immunohistochemistry. A series of 28 polypeptides were characterized among which the protein disulfide isomerase reduction – a protein instrumental to the unfolded protein response system - was shown to be reduced following PPARα agonists treatment while it was strongly increased in ischemia-reperfusion. CONCLUSIONS: Pre-treatment with PPARα agonist or atorvastatin show potential neuroprotective effects by inhibiting the PDI overexpression in conjunction with the preservation of other neuronal markers, several of which are associated with the regulation of protein homeostasis, signal transduction and maintenance of synaptic plasticity. This proteomic study therefore suggests that neuroprotective effect of PPARα agonists supposes the preservation of the expression of several proteins essential for the maintenance of protein homeostasis not necessarily directly linked to PPARα known-regulated targets. BioMed Central 2014-05-06 /pmc/articles/PMC4061923/ /pubmed/24944524 http://dx.doi.org/10.1186/1477-5956-12-24 Text en Copyright © 2014 Gelé et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Gelé, Patrick Vingtdeux, Valérie Potey, Camille Drobecq, Hervé Ghestem, Antoine Melnyk, Patricia Buée, Luc Sergeant, Nicolas Bordet, Régis Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke |
title | Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke |
title_full | Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke |
title_fullStr | Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke |
title_full_unstemmed | Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke |
title_short | Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke |
title_sort | recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061923/ https://www.ncbi.nlm.nih.gov/pubmed/24944524 http://dx.doi.org/10.1186/1477-5956-12-24 |
work_keys_str_mv | AT gelepatrick recoveryofbrainbiomarkersfollowingperoxisomeproliferatoractivatedreceptoragonistneuroprotectivetreatmentbeforeischemicstroke AT vingtdeuxvalerie recoveryofbrainbiomarkersfollowingperoxisomeproliferatoractivatedreceptoragonistneuroprotectivetreatmentbeforeischemicstroke AT poteycamille recoveryofbrainbiomarkersfollowingperoxisomeproliferatoractivatedreceptoragonistneuroprotectivetreatmentbeforeischemicstroke AT drobecqherve recoveryofbrainbiomarkersfollowingperoxisomeproliferatoractivatedreceptoragonistneuroprotectivetreatmentbeforeischemicstroke AT ghestemantoine recoveryofbrainbiomarkersfollowingperoxisomeproliferatoractivatedreceptoragonistneuroprotectivetreatmentbeforeischemicstroke AT melnykpatricia recoveryofbrainbiomarkersfollowingperoxisomeproliferatoractivatedreceptoragonistneuroprotectivetreatmentbeforeischemicstroke AT bueeluc recoveryofbrainbiomarkersfollowingperoxisomeproliferatoractivatedreceptoragonistneuroprotectivetreatmentbeforeischemicstroke AT sergeantnicolas recoveryofbrainbiomarkersfollowingperoxisomeproliferatoractivatedreceptoragonistneuroprotectivetreatmentbeforeischemicstroke AT bordetregis recoveryofbrainbiomarkersfollowingperoxisomeproliferatoractivatedreceptoragonistneuroprotectivetreatmentbeforeischemicstroke |